Brain Metastases, Non Small Cell Lung Cancer
Conditions
Brief summary
This is a single-arm, phase II study of dacomitinib in advanced EGFR-mutant NSCLC patients who have non-irradiated brain metastasis.
Interventions
DRUGDacomitinib
Secondary generation EGFR-tyrosine kinase inhibitor (TKI) (Dacomitinib) for EGFR mutant NSCLC patients with non irradiated brain metastasis
Sponsors
Samsung Medical Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Biopsy proven recurrent or metastatic NSCLC (adenocarcinoma) with major EGFR mutation (exon 19 deletion or Leu858Arg mutation without the Thr790Met) * No prior systemic treatment of advanced NSCLC (Neoadjuvant or adjuvant chemotherapy are allowed, without limitation on its treatment timing) * Age ≥20 years * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 * Had at least one measurable intracranial lesion as ≥ 5mm in the longest diameter by magnetic resonance imaging (MRI) (≥ 5mm by thin section (1.2mm) of brain MRI image, ≥ 10mm by less thin section(2.5mm) brain MRI ), which checked within 4 weeks before enrollment. If MRI slice thickness is not appropriate, we need to recheck Brain MRI * Number of brain metastasis =\>5 * Adequate organ function * Female subjects must either be of non-reproductive potential * Subject is willing and able to comply with the protocol * Signed written informed consent
Exclusion criteria
* Severe symptomatic brain metastasis, needing urgent control with radiotherapy or high dose steroid: the definition of high dose steroid is the equivalent dose of dexamethasone 10 mg or higher per day (mild symptoms controlled with low dose of steroid can be enrolled) * With leptomeningeal seeding * Exposure to EGFR-TKIs or other EGFR targeting agents at any time in either neoadjuvant or adjuvant setting * Local treatment (stereotatic radiosurgery or whole brain radiotherapy) for brain metastases * Uncontrolled systemic illness including uncontrolled hypertension, active bleeding, or active infection. * Past medical history of interstitial lung disease, drug induced interstitial lung disease, radiation pneumonitis which required steroid treatment * Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator. * Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| CNS objective response rate (Complete response or Partial response) | 1 year | The rate of CR or PR of CNS disease |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cumulative incidence of CNS failure by competing risk analysis | 1 year | To evaluate the CNS efficacy of dacomitinib |
| Extracranial objective response rate | 1 year | The rate of CR or PR |
| CNS progression-free survival | 1 year | Time from enrollment to CNS progression or death |
| Overall survival | 1 year | Time from enrollment to death of any cause |
| Safety by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 | 1 year | The % of side effect |
| Progression-free survival | 1 year | Time from enrollment to progression or death |
Countries
South Korea
Contacts
Primary ContactJong-Mu Sun, MD
Outcome results
None listed